Showing results (131-140 of 172) with videos related to
Sort By:
Pageof 18
Cancer Biotherapy & Radiopharmaceuticals|February 19, 2004
In vivo and in vitro detection of dopamine d2 receptors in uveal melanomasLisa Bodei, Leo J Hofland, Diego Ferone, et al.Clinical Endocrinology|August 19, 2011
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatinsFederico Gatto, Federica Barbieri, Monica Gatti, et al.European Journal of Endocrinology|January 21, 2015
Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrenceStephan Petersenn, Albert Beckers, Diego Ferone, et al.The Journal of Clinical Endocrinology and Metabolism|October 8, 2024
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1Diego Ferone, Pamela Freda, Laurence Katznelson, et al.Clinical Endocrinology|June 30, 2015
Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entryMarco Losa, Paolo Beck-Peccoz, Gianluca Aimaretti, et al.The Journal of Clinical Endocrinology and Metabolism|May 6, 2004
Dopamine receptor expression and function in corticotroph pituitary tumorsRosario Pivonello, Diego Ferone, Wouter W de Herder, et al.The Journal of Clinical Endocrinology and Metabolism|April 19, 2017
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter StudyAndrea Giustina, Gherardo Mazziotti, Salvatore Cannavò, et al.Oncotarget|April 29, 2017
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?Amira Mohamed, David Romano, Alexandru Saveanu, et al.Advances in Therapy|November 21, 2023
Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary GroupNicola Fazio, Massimo Falconi, Emanuela Foglia, et al.Journal of Endocrinological Investigation|October 12, 2024
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM)Francesco Panzuto, Manuela Albertelli, Maria Luisa De Rimini, et al.Pageof 18